
ARMACO boletim de **OCTOBER 2018 IGILÂNCIA**

Severe Cutaneous Adverse Reactions (SCAR) to Drugs - a reference* for healthcare professionals



The **incidence** of these reactions is low. It is estimated at two cases per million people for SJS and TEN, and at 1 out of every 1,000 to 10,000 new users of antiepileptic drugs for DRESS. Though rare, these reactions can be fatal or cause serious sequelae – an early diagnosis is crucial so that the offending drug can be immediately discontinued and appropriate treatment started.

SCARs are considered to be **non-immediate hypersensitivity reactions**. Their heterogeneity may be explained by activation of varying types of effector or regulator cells secreting specific cytokines. The following adapted table highlights their main clinical and histopathological features.

	Time between start of exposure to drug and start of reaction	General signs and symptoms	Cutaneous features	Laboratory	Major affected organs	Histopathology
SJS and TEN	4-28 days	Fever ≥38°C, flu-like syndrome, respiratory tract symptoms	Blisters, extensive sloughing (SJS < 10%, TEN ≥30%, SJS-TEN 10-30%), confluent erythema, atypical target lesions, purpura, Nikolsky's sign (skin detachment with sliding finger pressure)	Lymphopenia, transient neutropenia, renal impairment	Ears, nose and throat, lungs, Gl tract, liver, kidneys	Necrosis in whole thickness of epidermis, focal necrosis of skin appendages and keratinocytes, moderate dermal mononuclear cell infiltrate, negative direct immunofluorescence test
DRESS	2-6 weeks	Fever ≥38°C, flu-like syndrome	Maculopapular rash, erythroderma, oedema of the face or extremities, purpura, focal and monopolar mucosal involvement	Eosinophilia >700 cells/μL, atypical lymphocytes, raised transaminases, renal impairment, herpesvirus (HHV-6, HHV-7, EBV, CMV) reactivation, parvovirus B19 reactivation	Liver, kydneys, lungs, muscle, heart, pancreas, bone marrow, lymph nodes (in 2 or more sites)	Lichenoid infiltrate or eczematous pattern, focal keratinocyte necrosis, mononuclear infiltrate, focal eosinophil and neutrophil infiltrates, mild vasculitis
AGEP	1-11 days	Fever ≥38°C	Intertriginous erythema, oedema, disseminated sterile non-follicular pustules, postpustular pinpoint desquamation, Nikolsky's sign, oral mucosa rarely involved	Hyperleucocytosis, neutrophils ≥7000 cells/µL, mild eosinophilia	Rare: liver, lungs	Subcorneal or intraepidermal pustules, with or without papillary oedema, focal keratinocyte necrosis, sometimes neutrophilia and eosinophilia, mild vasculitis

Cont′d ►

VOLUME 22

NUMBER 10



Severe Cutaneous Adverse Reactions (SCAR) to Drugs – a reference* for healthcare professionals



▶ Cont'd

SSJ and TEN are viewed as variants in a **spectrum**. Typical dermatological features are often preceded by general manifestations. Two or more mucosae are affected in 80% of cases, also frequently preceding the skin lesions. Histological confirmation of whole-thickness epidermal necrosis and a negative direct immunofluorescence test are essential, though a specific diagnostic test or algorithm is not available. It should be noted that an **offending drug is found in 30% of cases** whereas in 15% causality associated with a medicine is unlikely.

The diagnosis of **DRESS** is difficult given the complexity of the natural evolution of this clinically heterogeneous syndrome, including visceral symptoms with or without skin involvement. The **prodromal stage** can precede the skin rash by two weeks, presenting with fever, lymphadenopathy, flu-like syndrome, pain or burning sensation, or pruritus. DRESS can cause reactivation of one or multiple members of the human herpesvirus family. Long-term relapses have also been described.

Should a diagnosis of SJS, TEN or DRESS be confirmed, the condition should be treated and followed up in a specialized unit. **A diagnosis of SJS or TEN in the first seven days** is associated with greater survival comparatively to a more delayed diagnosis.

AGEP is considered to be the least serious of the four, and is usually **transient and benign**. The first sites to be affected are the intertriginous areas (armpits, groin), the trunk and the upper extremities.

Causality assessment in a case of SCAR should take into account several factors, such as the case's specific clinical manifestations, the medicinal product's characteristics, and the time between drug administration and the appearance of symptoms. The drug exposure – start of SCAR time gap is usually short for AGEP, intermediate for SJS and TEN, and long for DRESS. A medicine that has been suspended before the start of a SCAR can still be suspected as a cause should it have a long half-life.

Other causality algorithms notwithstanding, the **ALgorithm for Drug causality in Epidermal Necrolysis (ALDEN)** has been validated to improve the causality assessment of individual cases of SJS and NET. It uses data on time since the medicine was first administered, on the medicine's pharmacokinetics, on suspension or reintroduction, as well as on notoriety (known high-risk medicines – see table below).

Drugs frequently associated with:						
SJS/TEN Creamer D et al. Br J Dermatol. 2016;174:1194–227	DRESS Cacoub P et al. Am J Med. 2011;124:588-97	AGEP Sidoroff A et al. Br. J.Dermatol. 2007;157:989–96.				
Allopurinol Carbamazepine Lamotrigine Nevirapine Non-steroidal antiinflammatory drugs Oxicam Phenobarbital Phenytoin Sulphamethoxazole and other sulfonamides Sulfasalazine	Abacavir Allopurinol Carbamazepine Lamotrigine Nevirapine Phenobarbital Phenytoin Sulfasalazine	Diltiazem Hydroxychloroquine Penicillins Quinolones Sulfonamides Terbinafine				

Early diagnosis and specialist treatment are essential so that long-term sequelae or fatal outcomes of SCAR can be prevented or limited. Physicians and other healthcare professionals need therefore stay up to to date and clinically aware for any potential causal associations between this type adverse reactions and unexpected medicinal products.

* Duong TA et al. Severe cutaneous adverse reactions to drugs. Lancet 2017; 390: 1996–2011

Ana Severiano

Educational Materials published in the Infomed product information webpage Click on the links. INN Materials? Target Medicinal product Online publication date Physicians: with experience in HIV therapy, hospital infectious Abacavir Hypersensitivity reactions diseases and internal medicine department directors. Abacavir + Lamivudine Pharmacists: hospital pharmacy service directors. Abacavir Mylan Abacavir + Lamivudina Mylan 30/10/2018 Adalimumab **Physicians:** hospital rheumatology, dermatology and **Guide on main safety risks** gastroenterology department directors. Amgevita **Patient alert card** Patients **Paediatric patient alert card** 12/10/2018

Educational Materials published in the <u>Infomed</u> product information webpage Click on the links.

INN Medicinal product	Target	Materials? Online publication date
Adrenaline	Physicians: respiratory medicine, paediatrics and allergy specialists.	Prescriber checklist
Epipen	Patients and/or caregivers	Educational brochure Educacional videoclip 26/10/2018
Alemtuzumab Lemtrada	Physicians: neurology.	<u>Guide (safety risks and monitoring)</u> Prescriber checklist
	Patients	Patient guide Alert card 02/10/2018
Atezolizumab Tecentriq	Physicians: pneumologists with experience in lung cancer treatment; urologists with experience in bladder cancer treatment; oncologists with experience in lung and/or bladder cancer treatment.	<u>Safety guide</u>
	Patients	Alert card 12/10/2018
Phentanyl	Physicians: oncologists, pain and palliative care specialists.	Guide (risk minimization)
PecFent	Pharmacists: community and hospital pharmacies.	
	Patients and healthcare providers	Patient and healthcare provider guide
		11/10/2018
Dimethyl fumarate Skilarence	Physicians: dermatologists.	Guide on the risk of serious infections 12/10/2018
Hydroxycarbamide	Physicians: haematology, oncology, endocrinology and paediatrics.	Treatment guide in sickle cell anaemia
Siklos	Patients	Patient guide – in sickle cell anaemia 31/10/2018
Methylphenidate	Physicians: paediatrics, neuropaediatrics and psychiatry.	Prescription guide
Metilfenidato Farmoz		Pre-prescription checklist
Metilfenidato Sandoz		Ongoing treatment monitoring checklist
		Ongoing treatment monitoring table
Ocriplasmin	Patients	<u>Treatment guide – pdf</u>
Jetrea		Treatment guide – audio CD 31/10/2018
Rituximab	Physicians: rheumatology and internal medicine.	Non-oncological indications
Rixathon	Physicians: haematologists and oncologists.	Alert card for chronic lymphocytic leukaemia
	Pharmacists: hospital. Nurses: hospital.	(CLL) and non-Hodgkin lymphoma (NHL)
	Patients	Non-oncological indications
Magnacium culnhata I	Physicians: gastroenterology.	Leaflet on the relevance of adequate hydration
Magnesium sulphate + Potassium sulphate +	y	· · · · · · · · · · · · · · · · · · ·

Compiled by Fernanda Marques and Magda Pedro

Communications to Healthcare Professionals published on the Infarmed <u>website</u>

Click on the links.

INN Medicinal product	Target	Comunication Online publication date
Ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin and prulifloxacin Products containing fluoroquinolones for systemic and inhalatory routes	Physicians: general/family medicine, ENT, pneumology, urology, nephrology, infectious diseases, internal medicine, cardiology, radiology and intensive medicine.	Risk of aortic aneurysm and dissection 09/10/2018
Dexamethasone Ozurdex	Physicians: ophthalmologists specialized in retina, at private and state clinics and hospitals.	Inspection finding of a silicone particle in implant List of marketed batches with confirmed particle presence and which were subjected to immediate recall (communication annex) 24/10/2018
Hydrochlorothiazide (single or in combination) Products containing hydrochlorothiazide	Physicians: general/family medicine, internal medicine, cardiology, nephrology, geriatrics and dermatology. Pharmacists: community and hospital pharmacies.	Risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) 12/10/2018
Ocriplasmin Jetrea	Physicians: ophthalmologists. Pharmacists: community and hospital pharmacies. Nurses: in ophthalmology departments.	0.375 mg/0.3 ml injectable solution <u>– no need for dilution before</u> <u>injection</u> 18/10/2018
Rivaroxaban Xarelto	Physicians: intervention cardiologists in state and private hospitals where TAVI procedures are undertaken; Portuguese Association of Cardiovascular Intervention (APIC).	Increased all-cause mortality, thromboembolic and haemorrhagic events, in patients undergoing transcatheter aortic valve implantation in prematurely discontinued clinical trial 03/10/2018
Sildenafil Revatio Viagra	Physicians: gynaecology and obstetrics.	Sildenafil should not be used for the treatment of intrauterine growth restriction 11/10/2018
Ulipristal EllaOne	Physicians: gynaecology and obstetrics, general/family medicine. Pharmacists: community.	Pregnancy Registry

Compiled by Fernanda Marques and Magda Pedro





Report an adverse drug reaction <u>here</u>. Find answers to your questions about the ADR Portal <u>here</u>.